![Barry L. Karger](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Barry L. Karger
Gründer bei BioAnalytix, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Alfonso Chang | M | - |
BioAnalytix, Inc.
![]() BioAnalytix, Inc. Information Technology ServicesTechnology Services BioAnalytix, Inc. develops and applies advanced analytic technologies. It offers advanced analytics, biologic therapeutics, mass spec, drug development and biopharma technologies. The company was founded by Barry L. Karger and Kirtland G. Poss in 2012 and is headquartered in Cambridge, MA. | - |
Michael Chao | M | - |
BioAnalytix, Inc.
![]() BioAnalytix, Inc. Information Technology ServicesTechnology Services BioAnalytix, Inc. develops and applies advanced analytic technologies. It offers advanced analytics, biologic therapeutics, mass spec, drug development and biopharma technologies. The company was founded by Barry L. Karger and Kirtland G. Poss in 2012 and is headquartered in Cambridge, MA. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Kirtland Poss | M | - |
BioAnalytix, Inc.
![]() BioAnalytix, Inc. Information Technology ServicesTechnology Services BioAnalytix, Inc. develops and applies advanced analytic technologies. It offers advanced analytics, biologic therapeutics, mass spec, drug development and biopharma technologies. The company was founded by Barry L. Karger and Kirtland G. Poss in 2012 and is headquartered in Cambridge, MA. | 9 Jahre |
Laszlo Takacs | M | - |
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | 10 Jahre |
András Guttman | M | - |
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | 10 Jahre |
Jean-Pierre Tirouflet | M | - |
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | - |
Hubertus V. Sulkowski | M | - |
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | - |
Wael Yared | M | 62 |
BioAnalytix, Inc.
![]() BioAnalytix, Inc. Information Technology ServicesTechnology Services BioAnalytix, Inc. develops and applies advanced analytic technologies. It offers advanced analytics, biologic therapeutics, mass spec, drug development and biopharma technologies. The company was founded by Barry L. Karger and Kirtland G. Poss in 2012 and is headquartered in Cambridge, MA. | 2 Jahre |
William Hancock | M | - |
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | 14 Jahre |
Elisabeth Rocolle-Teyssier | F | - |
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | - |
Sylvie le Gledic | M | - |
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Frankreich | 7 | 63,64% |
Vereinigte Staaten | 4 | 36,36% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Barry L. Karger
- Persönliches Netzwerk